Joseph McEvoy benefited from the 1948 Education Act: he was accepted into St Malachy’s College Belfast, where he excelled as a student.
My brother John Richard Findley came up as a mature student, after working in the computer industry.
(DOE/Lawrence Berkeley National Laboratory) Joint BioEnergy Institute researchers have identified a terpene called bisabolane as a potential biofuel for replacing diesel fuel. The researchers have also engineered two strains of microbes -- a bacteria and a yeast -- that can be used in the biosynthetic production of this clean, green, renewable and domestic alternative to diesel fuel.
In seeking to better understand how teosinte gave rise to corn, a scientific team has pinpointed one of the key genetic changes that paved the way for corn's domestication.
(DOE/Lawrence Berkeley National Laboratory) Joint BioEnergy Institute researchers have identified a terpene called bisabolane as a potential biofuel for replacing diesel fuel. The researchers have also engineered two strains of microbes -- a bacteria and a yeast -- that can be used in the biosynthetic production of this clean, green, renewable and domestic alternative to diesel fuel.
The JRC will webstream its upcoming international conference ‘Scientific Support for Food Security and Global Governance’ to make it available to a wider audience.
Research carried out by professors at Universidad Carlos III de Madrid analyzing how Spanish journalists use the main social networks shows that Twitter is the most widely used, particularly to disseminate information.
Joint BioEnergy Institute researchers have identified a terpene called bisabolane as a potential biofuel for replacing diesel fuel. The researchers have also engineered two strains of microbes -- a bacteria and a yeast -- that can be used in the biosynthetic production of this clean, green, renewable and domestic alternative to diesel fuel.
HORSHAM, Pa., Sept. 23, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.
